Dipeptidyl peptidase-4 (DPP-4) inhibitors, or gliptins, are a relatively new class of oral drugs for type 2 diabetes. These drugs block the DPP-4 enzyme metabolism of incretin hormones, including GLP-1 and GIP. In this issue of Diabetes News Nucleus, let us understand more about gliptins and the future of diabetes management with special focus on this new class of drugs.
Dr. Sanjay Kalra is an eminent endocrinologist based at Bharti Hospital, Karnal, India, and the Immediate Past President of the South Asian Federation of Endocrine Societies (SAFES). He holds an MBBS, MD, and DM, and is known for his contributions as a clinician, researcher, and writer. Dr. Kalra is the Past President of the Endocrine Society of India (ESI), President of the Indian Professional Association for Transgender Health (IPATH), and an Executive Committee Member as well as Chair of the Education Working Group at the International Society of Endocrinology (ISE). Additionally, Dr. Kalra serves as the Section Editor of EndoText, a PubMed-indexed textbook, and is the Editor-in-Chief of the Asian Journal of Diabetology. He lends his editorial expertise to numerous other publications, actively contributing to the advancement of endocrine science. His efforts extend beyond clinical practice and research, as he is deeply involved in spreading endocrine and diabetes awareness globally. In his leisure time, Dr. Kalra enjoys traditional Indian activities such as performing the folk dance Bhangra and practicing with the Mugdar, a traditional Indian club bell.
Please login to comment on this article